A Phase I Study of Safety, Pharmacokinetics, and Pharmacodynamics of Concurrent Everolimus and Buparlisib Treatment in Advanced Solid Tumors
Taofeek K. Owonikoko(UPMC Hillman Cancer Center), Fadlo R. Khuri(American University of Beirut Medical Center), Gabriel Sica(Emory University), Christina Wu(Mayo Clinic Hospital), Bradley Curtis Carthon(Emory University), Zhengjia Chen(Hunan University of Traditional Chinese Medicine), R. Donald Harvey(Emory University), Olatunji B. Alese(Emory University), Mehmet Asım Bilen(Emory Healthcare), Ragini R. Kudchagkar(Emory University), Colleen Lewis(Emory University), Bassel F. El‐Rayes(University of Alabama at Birmingham), Walid L. Shaib(Emory University), Mehmet Akce(Medizinische Hochschule Hannover), Conor Steuer(Emory University), Suresh S. Ramalingam(Emory University), Chao Zhang(Emory University), Wayne Harris(Emory University), David H. Lawson, Sagar Lonial(Emory University)
Cited by 14
Related Papers
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
|New England Journal of Medicine|2021|1.8k